Obstetrics

 
 APOSTEL VIII
 
 Dutch TRUFFLE
 
 2Close
 
 APRIL
 Highlow
 
 PC
 Quadruple P
 
 SIMPLE III
 
 Stop or Go?
 
 STRIDER
 > SUGAR-DIP
 
 KEUZEHULP IMPLEMENTATIE
 
 INDEX
 MOTHER
 NethOSS
 Ppromexil-III
 ALLO
 AMPHIA
 APOSTEL-I
 APOSTEL-II
 APOSTEL-III
 APOSTEL-IV
 
 Apostel VI
 ASB
 CHIPS
 DIGITAT
 ECV Implementation
 EuFis
 Fluxim
 GlucoMOMS
 HTA Longterm conseq.
 HTA Preference study
 HYPITAT
 HYPITAT-II
 HyRAS (Hypitat followup)
 Implementatie Tour
 IUPC
 PIMPP
 PPROMCerclage
 PPROMEXIL
 PreCare
 PROBAAT
 PROBAAT-II
 PROBAAT-S
 ProTWIN
 SimpleII
 STAN
 TeMpOH-1
 TeMpOH-3
 TOSTI
 TOTEM
 Triple P
 TRUFFLE
 WOMB study

 ABCD-study
 BIG CHANGE
 CAMPUR
 Cancer in pregnancy
 Doula study
 ECV tocolysis
 ECV Uterine relaxation
 EuroHeartSurvey
 FRUIT
 HP4ALL-PC
 HP4ALL-RS
 IMPACT
 INCAS
 IRIS
 Keizerlijk litteken
 MAKE
 OOPUS
 PRELHUDE
 PROMISES
 RAVEL
 SIMPLE
 STAN followup
 VET study
 VIS-project
 Wat bevalt beter
 ZAHARA II
 ZAHARA 3
 ZOBASII
 


SUGAR-DIP

Oral medication strategy versus insulin for diabetes in pregnancy



Go to the sugardip website

Objective:
To assess the clinical efficacy, safety, cost-effectiveness and patient experience of oral antidiabetic treatment as first-choice agents to treat GDM compared to the conventional insulin treatment strategy.

Studydesign:
Open label, multicenter, non-inferiority, randomized controlled trial(RCT).

Study population:

Pregnant women diagnosed with GDM, failing to reach glycemic control with dietary adjustments, requiring additional treatment with antidiabetic medication, between the gestational age of 16 to 34 weeks.

Inclusion criteria:

  • Women >    18 years old with a singleton pregnance
  • Pregnancy is complicated by gestational diabetes as per national guidelines
  • Indication for medical treatment
  • Gestational age of 16 to 34 weeks
  • Able to give informed consent
  • Able to understand Dutch or English
Inclusion criteria:
  • Suffering from severe medical or psychological comorbidities
  • Suffering from severe liver- or kidney failure
  • Pregnancy with a fetus affected by major congenital birth defects and/or chromosomal abnormalities
  • Pre-existing type I or II diabetes
Intervention:
Eligible women will be randomized for either treatment with oral antidiabetic medication consisting of metformin and if needed additional glibenclamide or insulin.

Outcome measures:
Primary outcome: large-for-gestational-age (LGA) defined as a birth weight >90th percentile.
Secondary outcomes: maternal diabetic endpoints (hypoglycemia, time to reach glycemic control, HbA1c), maternal weight gain, treatment failure, pregnancy complications (pregnancy related hypertensive disorders, preterm delivery), birth injury, Caesarean section,neonatal complications (hypoglycemia, hyperbilirubinemia, NICUadmission), umbilical cord markers for hyperinsulinemia, patient satisfaction and health-related quality of life (EQ5-5D-5L and DTSQ questionnaires), costs from a societal perspective.

Power/data analysis:

This study will be a two-armed non-inferiority trial(metformin/glibenclamide versus insulin). The anticipated incidence of the primary outcome measure (LGA) is 20% in both groups. We have set the non-inferiority limit at 8%, which is equivalent to excluding a relative risk greater than 1.4. With a one-sided significance level() of 0.025 and a power of 0.8, the sample size was calculated at393 patients in each arm. Accounting for a loss to follow-up of 3%,810 patients are needed.

Economic evaluation:
Acost-effectiveness analysis will be performed, taking into accountthe costs of the different treatment strategies, health-care consumption and productivity losses from inclusion in the study up to 6 weeks postpartum.

Time schedule:
36 months: 6 months preparation, 24 months inclusion, 6 months analysis and report.

Project leaders:

Dr. B.B. van Rijn, gynaecologist, UMC Utrecht
Prof. dr. A. Franx, gynaecologist, UMC Utrecht
Prof. dr. J.H. de Vries, internal medicine endocrinologist, AMC Amsterdam

Health technology Assessment:

Dr. J.E. Bosmans, assistant professor, Department of Health & Science, VU Amsterdam

Methodology:

Dr. Christiana Naaktgeboren, assistant professor, UMC Utrecht, c.naaktgeboren@umcutrecht.nl

Subsidy:
ZonMw

Contact (researcher):
Drs. Leon de Wit, UMC Utrecht, l.dewit-3@umcutrecht.nl